Data on VIVUS' Qnexa To Be Featured at the American Society of Hypertension Annual Meeting
MOUNTAIN VIEW, Calif., April 28 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa®, an investigational drug candidate, will be presented at the American Society of Hypertension 25th Annual Scientific Meeting and Exposition in New York, NY. Suzanne Oparil, MD, professor of medicine, physiology and biophysics and director, vascular biology and hypertension program, division of cardiovascular disease, department of medicine at the University of Alabama at Birmingham, will make an oral presentation during the late-breaking clinical trials session entitled: "Once-Daily, Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) Improves Blood Pressure and Results in Weight Loss in Overweight/Obese Patients Through 28 Weeks."
"We are pleased to have a presence at this year's ASH meeting, and that Dr. Oparil will be sharing these analyses highlighting the impact of Qnexa treatment and the resulting improvement in blood pressure in obese hypertensive patients with our colleagues in the medical community," stated Leland Wilson, chief executive officer of VIVUS. "This is an exciting time for VIVUS. We believe that Qnexa, if approved, may play a significant role in the treatment of patients living with co-morbidities that result from their obesity. We are actively pursuing a comprehensive presentation and publication strategy, and look forward to additional presentations in the near future."
Following are details about the upcoming presentation:
American Society of Hypertension 25th Annual Scientific Meeting and Exposition, |
|
New York Hilton Hotel & Towers, New York, NY |
|
Date and Time: Tuesday, May 4, 2010, 7:45-9:45 AM |
|
Location: West Ballroom |
|
Session: Late-Breaking Clinical Trials |
|
Presentation Title: Once-Daily, Low-Dose, Controlled-Release Phentermine/Topiramate (PHEN/TPM CR) Improves Blood Pressure and Results in Weight Loss in Overweight/Obese Patients Through 28 Weeks |
|
Chairs: Henry R. Black, MD and George L. Bakris, MD |
|
Presenter: Suzanne Oparil, MD |
|
About VIVUS
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead product in clinical development, Qnexa®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2009 and periodic reports filed with the Securities and Exchange Commission.
CONTACT: |
|||
VIVUS, Inc. |
Investor Relations: |
The Trout Group |
|
Timothy E. Morris |
Brian Korb |
||
Chief Financial Officer |
646-378-2923 |
||
650-934-5200 |
|||
Media Relations: |
Pure Communications, Inc. |
||
Dan Budwick |
|||
973-271-6085 |
|||
SOURCE VIVUS, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article